ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ascendis Pharma A/S
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 11, 2026
$229.95+4.70 (+2.09%)
Close on Oct 19, 2026
Ascendis Pharma A/S revenue by segment
By business segment
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe [member] | €157.71M | €135.94M | €120.95M | €191.14M | €165.91M | €143.10M | €123.34M | €15.29M | €7.52M | €2.44M | €869.00K | €507.00K | 15.1% | -4.9% |
| Rest of World [member] | €50.50M | €48.17M | €52.80M | €50.02M | €31.82M | €11.54M | €7.19M | €76.69M | €76.18M | – | €74.17M | – | 4.8% | +58.7% |
| Denmark | €16.00M | €15.00M | €12.90M | €104.50M | €100.40M | €97.80M | €95.40M | – | – | – | – | – | 1.5% | -84.1% |
| North America [member] | – | – | – | €405.65M | €293.28M | €214.23M | €233.22M | €235.45M | €233.93M | €251.29M | €191.68M | €146.79M | – | – |
| Asia [Member] | – | – | – | – | – | – | – | – | €76.18M | €75.30M | €74.17M | €4.61M | – | – |
From the segment and revenue-disaggregation notes of Ascendis Pharma A/S's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.